Get To Know Us

Our Expertise

Guided by category pioneers and inventors of this technology as well as seasoned entrepreneurs, we are rigorously pursuing our mission to improve outcomes for individuals affected by challenging chronic respiratory diseases.

Board of Directors

Peter G. Kleinhenz

Co-founder & Board Chair

Learn More

Michael Triplett, Ph.D.

Co-founder & Board Member

Learn More

Bill Baumel

Board Member

Learn More

Chuck Bramlage

Board Member

Learn More

Larry Edwards

Board Member

Learn More

David Richards

Board Member

Learn More

Douglas Thomson

Board Member

Learn More

Wayne Embree

Board Observer

Learn More

Faith Voinovich

Board Observer

Learn More

Scientific Advisors

Jeffrey Almond, Ph.D.

Scientific Advisory Board Member

Learn More

Bruce Forest, M.D.

Scientific Advisory Board Member

Learn More

Palani Palaniappan, Ph.D.

Scientific Advisory Board Member

Learn More

Obadiah Plante, Ph.D.

Scientific Advisory Board Member

Learn More

Brian Price, Ph.D.

Scientific Advisory Board Member

Learn More

George Siber, M.D.

Scientific Advisory Board Member

Learn More

David Zarley, Ph.D.

Scientific Advisory Board Member

Learn More

Scientific Founders

Lauren O. Bakaletz, Ph.D.

Scientific Co-founder

Learn More

Steven D. Goodman, Ph.D.

Scientific Co-founder

Learn More

Juliana Woda, Ph.D.

Scientific Co-founder

Learn More

Strategic Advisors

Stephen Hoffman, M.D., Ph.D.

Strategic Advisor

Learn More

Paul Westberg, MBA

Strategic Advisor

Learn More
Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.